Literature DB >> 2894410

Regulation of transmitter gamma-aminobutyric acid (GABA) synthesis and metabolism illustrated by the effect of gamma-vinyl GABA and hypoglycemia.

R E Paulsen1, F Fonnum.   

Abstract

The effect of different treatments on amino acid levels in neostriatum was studied to throw some light on the synthesis and metabolism of gamma-aminobutyric acid (GABA). Irreversible inhibition of GABA transaminase by microinjection of gamma-vinyl GABA (GVG) led to a decrease in aspartate, glutamate, and glutamine levels and an increase in the GABA level, such that the nitrogen pool remained constant. The results indicate that a large part of brain glutamine is derived from GABA. Hypoglycemia led to an increase in the aspartate level and a decrease in glutamate, glutamine, and GABA levels. The total amino acid pool was decreased compared with amino acid levels in normoglycemic rats. GVG treatment of hypoglycemic rats led to a decrease in the aspartate level and a further reduction in glutamate and glutamine levels. In this case, GABA accumulation continued, although the glutamine pool was almost depleted. The GABA level increased postmortem, but there were no detectable changes in levels of the other amino acids. Pretreatment of the rats with hypoglycemia reduced both glutamate and glutamine levels with a subsequent decreased postmortem GABA accumulation. The half-maximal GABA synthesis rate was obtained when the glutamate level was reduced by 50% and the glutamine level was reduced by 80%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894410     DOI: 10.1111/j.1471-4159.1988.tb10586.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  The rate of turnover of cortical GABA from [1-13C]glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA).

Authors:  D Manor; D L Rothman; G F Mason; F Hyder; O A Petroff; K L Behar
Journal:  Neurochem Res       Date:  1996-09       Impact factor: 3.996

Review 2.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

3.  Initial experience with seven tesla magnetic resonance spectroscopy of hypothalamic GABA during hyperinsulinemic euglycemia and hypoglycemia in healthy humans.

Authors:  A Moheet; U E Emir; M Terpstra; A Kumar; L E Eberly; E R Seaquist; G Öz
Journal:  Magn Reson Med       Date:  2013-02-19       Impact factor: 4.668

Review 4.  In situ measurements of enzyme activities in the brain.

Authors:  P Kugler
Journal:  Histochem J       Date:  1993-05

5.  Alterations of GABA metabolism and seizure susceptibility in the substantia nigra of the kindled rat acclimating to changes in osmotic state.

Authors:  C F Baxter; C C Oh; C G Wasterlain; L K Ozaki; R A Baldwin
Journal:  Neurochem Res       Date:  1991-03       Impact factor: 3.996

6.  Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma.

Authors:  W Löscher; D Hörstermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

7.  SAT1, A Glutamine Transporter, is Preferentially Expressed in GABAergic Neurons.

Authors:  Tom Tallak Solbu; Mona Bjørkmo; Paul Berghuis; Tibor Harkany; Farrukh A Chaudhry
Journal:  Front Neuroanat       Date:  2010-02-08       Impact factor: 3.856

8.  Evidence using in vivo microdialysis that aminotransferase activities are important in the regulation of the pools of transmitter amino acids.

Authors:  A H Bakkelund; F Fonnum; R E Paulsen
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

9.  Changes in evoked potentials and amino acid content during fluorocitrate action studied in rat hippocampal cortex.

Authors:  J Berg-Johnsen; R E Paulsen; F Fonnum; I A Langmoen
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.